Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Márcia Waddington‐Cruz(Université Paris-Sud), Daniel J. Lenihan(Saint Francis Medical Center), Claudio Rapezzi(University of Ferrara), Jonas Wixner(Umeå University), Hans Nienhuis(University Medical Center Groningen), Hartmut Schmidt(Université Paris-Sud), Burkhard Gess(RWTH Aachen University), José González‐Costello(British Heart Foundation), Marco Luigetti(Università Cattolica del Sacro Cuore), Saša Živković(University of Pittsburgh), Johan Van Cleemput, Jan Kiszko(Pfizer (United States)), Doug Chapman(Pfizer (United States)), Annabel Wang, Yoshiki Sekijima(Shinshu University), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Ivaylo Tarnev(Alexandrovska Hospital), Fábio Barroso(Université Paris-Sud), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Isabel Conceição(Université Paris-Sud), Arnt V. Kristen(Heidelberg University), Francisco Muñoz Beamud(Hospital Juan Ramón Jiménez), Brian Drachman(Penn Presbyterian Medical Center), Stephen S. Gottlieb(University of Maryland, Baltimore), Felix Darstein, Marcelo Rugiero, Olivier Lairez(Hôpital Rangueil), Leslie Amass(Pfizer (United States)), David B. Adams(Medical University of South Carolina), Roberto Fernández‐Torrón(Biogipuzkoa Health Research Institute), Josep Maria Campistol Plana(Hospital Clínic de Barcelona), Giampaolo Merlini(University of Pavia), Soon-Chai Low(Monash University Malaysia), Taro Yamashita(Kanazawa University), Teresa Coelho(Universidade do Porto), Sonoko Misawa(Institute of Neurological Sciences), Rayomand Press(Karolinska University Hospital), Juan González Moreno, Yeşim Parman(Université Paris-Sud), Angela Dispenzieri(Mayo Clinic), Pablo García Pavía(Alexandrovska Hospital), Theodoros Kyriakides(University of Nicosia)
Cited by 48
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k